Innovative RNA Profiling in Cancer Cells

这项建议的最终目标是开发和商业化一种新的、强大的检测系统，用于癌症相关研究中基因转录本的扩增和检测。具体地说，我们的专有技术旨在为两种类型的应用提供工具。首先，我们将开发一种可用于体外RNA扩增的检测系统。它将为研究癌细胞中的基因表达提供有效的工具。它还可用于检测癌症样本中的感染性病原体。其次，我们将测试使用我们的技术检测实体癌标本中基因表达的可行性。因此，可以直接在这些样本上监测表达转录本的空间分布。我们还计划致力于将我们的系统集成到一个与现代技术兼容的技术平台，如微阵列、纳米颗粒检测和光学扫描。利用这项技术对癌症进行分子图谱分析将使系统分析转录启动、选择性剪接或RNA稳定性的扰动成为可能。整个系统有望在基础、临床前和临床癌症研究中具有广泛的应用潜力。拟议的商业应用：拟议的技术将被开发成可销售的产品，如用于基因表达检测的实验室试剂盒或现场试剂盒。其他应用格式可以在该技术平台上构建。特别是，我们将与其他公司合作开发分析系统，用于高通量筛查与癌症相关的基因表达变化。由于其在生物医学领域的巨大潜力，预计这些系统的盈利能力将非常高。

The ultimate goal of this proposal is to develop and commercialize a novel and powerful assay system for amplification and detection of gene transcripts in cancer-related studies. Specifically, our proprietary technology is targeted to providing tools for two types of applications. First, we will develop an assay system that can be used for in vitro RNA amplification. It will provide effective tools for studies of gene expression in cancer cells. It can also be used for detecting infectious agents in cancer samples. Second, we will test the feasibility of using our techniques for detection of gene expression in solid cancer specimens. Thus spatial distribution of expressed transcripts can be monitored directly on these samples. We also plan to devote our efforts to integrate our system into a technology platform that is compatible with modern techniques such as microarray, nanoparticle detection, and optical scanning. Molecular profiling of cancer with this technology will enable systematic analysis of perturbations of transcription initiation, alternative splicing, or RNA stability. The entire system is expected to have wide potential for applications in basic, preclinical and clinical cancer research. PROPOSED COMMERCIAL APPLICATIONS: The proposed technology will be developed into marketable products such as lab kits or field kits for gene expression detection. Other application formats can be build upon the technology platform. Particularly, we will cooperate with other companies to develop analysis systems for high-throughput screening of cancer-related alterations of gene expression. The profitability of these systems is expected to be very high because of their enormous potential in biomedical field.